CCTA

Newsweek Selects Caristo Diagnostics as One of World's Best Digital Health Companies

Retrieved on: 
Monday, April 29, 2024
Inflammation, Coronary artery disease, Holon, Heart, Newsweek, Disease, Cardiovascular Research, Stroke, Diagnosis, Digital health, Patient, Splenic infarction, Cari, JACC, European Heart Journal, CCTA, Algorithm, Health, Medical device

OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.

Key Points: 
  • OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.
  • Newsweek's inaugural ranking of the World's Best Digital Health Companies includes 400 companies in seven segments including diagnostics, health records, medical management and telehealth.
  • The ranking is based on in-depth analysis of thousands of companies' financial performance and traffic data for websites and apps.
  • "Caristo is honored to be recognized by Newsweek as one of the World's Best Digital Health Companies.

Newsweek Selects Caristo Diagnostics as One of World's Best Digital Health Companies

Retrieved on: 
Monday, April 29, 2024
Inflammation, Coronary artery disease, Holon, Heart, Newsweek, Disease, Cardiovascular Research, Stroke, Diagnosis, Digital health, Patient, Splenic infarction, Cari, JACC, European Heart Journal, CCTA, Algorithm, Health, Medical device

OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.

Key Points: 
  • OXFORD, England, April 29, 2024 /PRNewswire/ -- Caristo Diagnostics , a leading cardiac disease diagnostics company, has been named by Newsweek as one of World's Best Digital Health Companies in diagnostics.
  • Newsweek's inaugural ranking of the World's Best Digital Health Companies includes 400 companies in seven segments including diagnostics, health records, medical management and telehealth.
  • The ranking is based on in-depth analysis of thousands of companies' financial performance and traffic data for websites and apps.
  • "Caristo is honored to be recognized by Newsweek as one of the World's Best Digital Health Companies.

Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually

Retrieved on: 
Monday, April 29, 2024
Technology, Insurance, Health Technology, Professional Services, Cardiology, Health Insurance, Software, General Health, Health, Artificial Intelligence, Use, Radiation, University, Part, Telehealth, Diagnosis, AUC, Hospital, SPECT, Care, Cardiovascular disease, Prevalence, Molina Healthcare, Methylation, American Medical Association, Death, DNA methylation, MD, Doctor of Philosophy, CHD, Advances in Therapy, DNA, Algorithm, Patient, Moyamoya disease, CPT, PLA, Medicare, Biomarker, Intermountain Health, Associate, Medicine, VBC, Economics, CCTA, Journal, American Heart Association

PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.

Key Points: 
  • PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD.
  • The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions.
  • The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated $113.6 million saved per year for a plan with one million members.
  • These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management.

Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers

Retrieved on: 
Tuesday, April 23, 2024
University, Cancer, NHS, Risk, Coronary artery disease, CDC, Heart, VCL, MD, Mace, Partnership, Research, MRCP, Atherosclerosis, Patient, Splenic infarction, Death, Chest pain, Artery, Plaque, Imaging, CCTA

OXFORD, England and SURREY, England , April 23, 2024 /PRNewswire/ -- Surrey Cardiovascular Clinic (SCVC), Southern England's leading centre of excellence for the prevention and treatment of cardiovascular and cancer issues, has partnered with Imaging provider VCL SURREY and Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • SCVC will provide the CaRi-Heart AI-based cardiac assessment as a central part of the organisations 's employee wellness initiative for UK employers.
  • In combination with the programme's other tests, Cari-Heart provides the ability to predict future heart attacks and atherosclerosis many years before symptoms occur.
  • We are pleased to announce our partnership with Surrey Cardiovascular Clinic and their imaging partner VCL Surrey to enhance accessibility to CaRi-Heart technology for employees throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.
  • The CaRi-Heart technology is currently in clinical use in various NHS and private hospitals in the UK, as well as within the EU and Australia.

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

Retrieved on: 
Tuesday, March 26, 2024
Nuclear, Education, Coronary artery disease, Disease, Safety, Partnership, Physiology, Anatomy, Patient, Journal, Biomarker, AI, Death, Plaque, Society, CAD, CCTA, Charleston Area Medical Center, MACE, Cone Health, Collection, FDA, Physician, IVUS, Hospital

The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).

Key Points: 
  • The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronary artery disease (CAD).
  • The DECODE study showed that clinicians using the HeartFlow Plaque Analysis changed their management decisions for 66% of patients compared to CCTA alone across various patient presentations and disease stages.
  • “We believe real-world prospective data from the new DECIDE Registry will empower clinicians with enhanced patient insights leveraging HeartFlow Plaque Analysis to improve patient outcomes.
  • The primary endpoint for this registry will highlight change in medical management after HeartFlow Plaque Analysis compared to after CCTA alone.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Retrieved on: 
Thursday, March 28, 2024
FDA, Health, Technology, Clinical Trials, Artificial Intelligence, Cardiology, Diagnosis, Coronary ischemia, Patient, Myocardial perfusion imaging, Journal, Ischemia, MD, American College, CCTA, Stenosis, Atherosclerosis, SPECT, Medical device

The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.

Key Points: 
  • The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.
  • For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up.
  • Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.
  • These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580.

Heart & Lung Health selects Caristo Diagnostics AI technology to provide early diagnosis of coronary artery disease UK-wide

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Lung cancer, Chest pain, Information technology, Radiology, Coronary artery disease, Partnership, Risk, University, Patient, Lung, Calcium, National Health Service, NHS, Research, Hospital, RadNet, Artificial intelligence, Death, Plaque, Artery, Mace, CCTA, Heart, HLH, Health, Medical device

OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH), a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH) , a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics , a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.
  • Many will undergo a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease caused by plaques that narrow or block the arteries that supply blood to the heart.
  • "Early diagnosis and interventions have the potential to significantly improve health outcomes for thousands of patients at risk of coronary artery disease.
  • We are pleased to announce our partnership with Heart & Lung Health, aiming to enhance accessibility to CaRi-Heart technology for patients throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

Retrieved on: 
Thursday, February 22, 2024
Software, Research, General Health, Data Management, Medical Devices, Technology, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, CCTA, Circulant matrix, MD, Physician, Pathology, Food, FFR, American Medical Association, Food and Drug Administration, Patient, Diagnosis, Category, Coronary artery disease, Medical imaging

The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.

Key Points: 
  • The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.
  • The Category I CPT® code is an addition to the Category III CPT® codes (CPT® 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronary atherosclerosis analysis.
  • “The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease,” said James P. Earls, MD, Chief Medical Officer of Cleerly.
  • The application of Cleerly ISCHEMIA supports improvements in physician certainty, guides medical therapy decision making, and reduces unnecessary invasive and non-invasive testing2-6.